X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Future Biotech Platforms Likely To Depend Primarily On Urine

Content Team by Content Team
13th December 2022
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A mechanism that employs urea to begin the manufacturing of proteins in the massive amounts required by the biotech industry has been developed by researchers at the Universities of Birmingham and Aston.

Typically, in this procedure, little DNA fragments are added to bacteria like E.coli to induce them to overproduce particular proteins. It was initially developed in the 1970s and is now a well-known technology. However, inducer molecules, which can be expensive and frequently require special management, like refrigeration—typically cause overproduction.

The researchers have created a process that is less complicated, more affordable, and employs components that are readily available by substituting urea.

The scientists looked at both refined urea and the urea included in typical garden fertilisers in a recent study that was published in the journal New Biotechnology. They demonstrated that any source could produce results that were comparable.

Their objective is to make this technology accessible to biotech companies that want to investigate how to maximise their operations while also keeping their costs down, according to co-author and professor Steve Busby of the University of Birmingham’s School of Biosciences.

The scientists also demonstrated that by adjusting the doses used, it was feasible to precisely control the levels of protein induced by the urea molecule. To prevent hurting or wearing out the host microorganisms, it’s crucial to do this. They discovered it was possible to maximise output to levels comparable to those generated with medium-strength promoters, which are currently the norm in the biotech sector.

The research expands on previous work in which the scientists showed that nitrate, a readily available, affordable, and stable inorganic ion, may also be employed as a trigger. Since nitrate is frequently included in many commercial fertilisers and even some garden fertilisers, it is constantly accessible, even in places where other types of promoter chemicals would not be.

The School of Biosciences’ Dr. Joanne Hothersall, who is a co-author on the paper, said that both urea and nitrate will become much more easily accessible and easier to use in regions where infrastructure prevents access, for example when sustaining a cold supply chain is difficult. They anticipate that these novel methodologies will present fresh research opportunities for the biotech sector.

The Biotechnology and Biological Sciences Research Council, a division of UK research and innovation, provided funding for the study.

Previous Post

NICE Methodology Raises Concerns For Kidney Research UK

Next Post

Canadian And US Developers To Test Psychedelic Drugs In UK

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Canadian And US Developers To Test Psychedelic Drugs In UK

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In